Scott & White Healthcare pathologist is co-investigator on breast cancer study
Key points
- In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells.
- Velusamy Rangasamy and Ajay Rana, Ph.D., are also the lead authors on the study and are based at Loyola University Medical Center in Chicago where Dr.
- "What we know is that not all breast tumors are the same and if a tumor is estrogen-receptor positive, it's possible that chemotherapy isn't going to be as effective as it could be," said Dr.
- "These findings are important because efficiently killing estrogen receptor positive (ER+) breast cancer cells with currently available chemotherapy is a challenging task and many times these ER+ breast tumors don't respond to classical chemotherapy," said Dr.
In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells. The most common type of breast cancer is "estrogen-receptor positive" breast cancer.
Velusamy Rangasamy and Ajay Rana, Ph.D., are also the lead authors on the study and are based at Loyola University Medical Center in Chicago where Dr. Rana is a professor of pharmacology.
"What we know is that not all breast tumors are the same and if a tumor is estrogen-receptor positive, it's possible that chemotherapy isn't going to be as effective as it could be," said Dr. Rao. "This is why we see some breast cancer patients on chemo that isn't working like it should. With this additional information regarding estrogen, it could help us create more targeted therapies in the future."
"These findings are important because efficiently killing estrogen receptor positive (ER+) breast cancer cells with currently available chemotherapy is a challenging task and many times these ER+ breast tumors don't respond to classical chemotherapy," said Dr. Rana. "Our research identified an alternative cellular protein which can serve as a viable target for ER+ breast cancer treatment."
Dr. Rao went on to say that "with this research we found that in order to make cancer drugs work better, we may need to give patients a different drug and this could possibly shorten the duration of their chemotherapy course if we knew more."
"Our work suggests that any drugs/agents that will activate this protein will sensitize the ER+ breast cancer cells toward commonly used chemotherapies. We have been working to find the drugs/agents that can activate this protein and kill the ER+ cancer cells," said Dr. Rana.
Dr. Rana explained that "these findings are encouraging but further research is needed to find how this cellular pathway could be utilized to target estrogen positive breast cancer cells."
###
Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsWhites take supplemental breast cancer therapy more often than blacks
A new study finds that white women more frequently take more of the life-prolonging supplemental therapies used to treat breast cancer than African-American women. African-Americans whose cancer had spread to the lymph…
9 October 2007
NewsDifferences observed between black and white women in use of breast cancer therapy
A new study finds treatment for breast cancer differs between African-American women and white women, though the differences are partly dependent on insurance type. The study appears in the November 15, 2007 issue of…
9 October 2007
NewsMale breast cancer worse for blacks than whites
While rare, breast cancer can occur in men. When it does, mortality is three times higher among black men than white men, according to a new study. The researchers note in the March 20th Journal of Clinical Oncology…
8 April 2007
